Intracranial Outcomes of 1L Selpercatinib in Advanced RET fusion-positive (RET plus ) NSCLC: LIBRETTO-431 study

被引：0

作者：

Perol, Maurice ^{[1
]}

Solomon, Ben J. ^{[2
]}

Goto, Koichi ^{[3
]}

Park, Keunchil ^{[4
]}

Nadal, Ernest ^{[5
]}

Bria, Emilio ^{[6
]}

Martin, Claudio ^{[7
]}

Bar, Jair ^{[8
]}

Williams, Justin ^{[9
]}

Puri, Tarun ^{[9
]}

Li, Jian ^{[10
]}

Uh, Minji ^{[9
]}

Lin, Boris ^{[9
]}

Zhou, Caicun ^{[11
]}

Pruthi, Aarohan ^{[9
]}

机构：

[1] Ctr Leon Berard, Lyon, France

[2] Peter MacCallum Canc Inst, Melbourne, Vic, Australia

[3] Natl Canc Ctr Hosp East, Chiba, Japan

[4] Samsung Med Ctr, Seoul, South Korea

[5] Inst Catala Oncol, Barcelona, Spain

[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy

[7] Inst Alexander Fleming, Buenos Aires, DF, Argentina

[8] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel

[9] Eli Lilly, Indianapolis, IN USA

[10] Loxo Lilly, Indianapolis, IN USA

[11] Shanghai Pulm Hosp, Shanghai, Peoples R China

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

259

引用

页码：138 / 138

页数：1

共 50 条

[41] Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in ret fusionpositive advanced non-small-cell lung cancer: interim analysis of LIBRETTO-431
Goto, Koichi
Novello, Silvia
Garrido, Pilar
Dooms, Christophe
Alatorre-Alexander, Jorge
Reinmuth, Niels
Gilligan, Adrienne
Payakachat, Nalin
Bence-Lin, Aimee
Cocks, Kim
Worthy, Gill
Zhou, Caicun
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 246 - 246
[42] Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
Lu, Shun
Cheng, Ying
Huang, Dingzhi
Sun, Yuping
Wu, Lin
Zhou, Chengzhi
Guo, Ye
Shao, Jingxin
Zhang, Wanli
Zhou, Jianying
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[43] Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib.
Murciano-Goroff, Yonina R.
Falcon, Christina J.
Lin, Sabrina T.
Dhawan, Aradhika
Grimaldi, Grace
Liu, Dazhi
Wilhelm, Clare
Thomas, Reeja
Iasonos, Alexia
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC
De Carlo, Elisa
Bertoli, Elisa
Schiappacassi, Monica
Stanzione, Brigida
Del Conte, Alessandro
Doliana, Roberto
Spina, Michele
Bearz, Alessandra
FRONTIERS IN ONCOLOGY, 2024, 14
[45] Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial (JUNR, 10.1200/PO.22.00708, 2023)
Cheng
JCO PRECISION ONCOLOGY, 2023, 7
[46] Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial
Minchom, Anna
Tan, Aaron C.
Massarelli, Erminia
Subbiah, Vivek
Boni, Valentina
Robinson, Bruce
Wirth, Lori J.
Hess, Lisa M.
Jen, Min-Hua
Kherani, Jennifer
Olek, Elizabeth
McCoach, Caroline E.
ONCOLOGIST, 2022, 27 (01) : 22 - 29
[47] CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
Perol, Maurice
Solomon, Benjamin J.
Goto, Koichi
Park, Keunchil
Nadal, Ernest
Bria, Emilio
Martin, Claudio
Bar, Jair
Williams, Justin N.
Puri, Tarun
Li, Jian
Uh, Minji K.
Lin, Boris K.
Zhou, Caicun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (21) : 2500 - 2505
[48] LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
Tsuboi, Masahiro
Goldman, Jonathan W.
Wu, Yi-Long
Johnson, Melissa L.
Paz-Ares, Luis
Yang, James Chih-Hsin
Besse, Benjamin
Su, Weiji
Chao, Bo H.
Drilon, Alexander
FUTURE ONCOLOGY, 2022, 18 (28) : 3133 - 3141
[49] Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial
Lu, Shun
Zheng, Xiangqian
Sun, Yuping
Huang, Dingzhi
Wu, Lin
Ji, Qinghai
Zhou, Chengzhi
Zhou, Jianying
Guo, Ye
Ge, Minghua
Ding, Ding
Shao, Jingxin
Zhang, Wanli
Gao, Ming
Cheng, Ying
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[50] AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion-positive advanced/metastatic NSCLC.
Popat, Sanjay
Felip, Enriqueta
Kim, Edward S.
de Marinis, Filippo
Cho, Byoung Chul
Wermke, Martin
De langen, Adrianus
Ferrara, Roberto
Kanzler, Stephan
Cecere, Fabiana Letizia
Galetta, Domenico
Lee, Dae Ho
Gregorc, Vanesa
Rodrigues, Ana
Britschgi, Christian
Rahman, Ahmadur
Ndunda, Diana
Noe, Johannes
Lu, Danny
Besse, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →